Clinical Trial Update: Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia [Phase 2, Phase 3]

View source ↗

Summary

A randomized, controlled study of IFX-1 (vilobelimab) in patients with severe COVID-19 pneumonia completed Phase 2/3 with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• IFX-1 (vilobelimab)

Snippet

Sponsor: InflaRx GmbH | Conditions: Severe COVID-19 Pneumonia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-06-05